The PE Ratio as of November 2024 (TTM) for Rani Therapeutics Holdings, Inc. (RANI) is -2.04

According to Rani Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.04. This represents a change of -25.50% compared to the average of -2.74 of the last 4 quarters.

Rani Therapeutics Holdings, Inc. (RANI) Historical PE Ratio (quarterly & annually)

How has RANI PE Ratio performed in the past?

The mean historical PE Ratio of Rani Therapeutics Holdings, Inc. over the last ten years is -6.39. The current -2.04 PE Ratio has changed 3.09% with respect to the historical average. Over the past ten years (40 quarters), RANI's PE Ratio was at its highest in in the September 2023 quarter at -1.51. The PE Ratio was at its lowest in in the June 2021 quarter at -23512.26.

Rani Therapeutics Holdings, Inc. (RANI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Rani Therapeutics Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Rani Therapeutics Holdings, Inc. (RANI) Average PE Ratio

How has RANI PE Ratio performed in the past?

The current PE Ratio of Rani Therapeutics Holdings, Inc. (RANI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Rani Therapeutics Holdings, Inc. (RANI) PE Ratio vs. Peers

How is RANI’s PE Ratio compared to its peers?

Rani Therapeutics Holdings, Inc.’s PE Ratio is less than Vincerx Pharma, Inc. (-0.47), less than Tenaya Therapeutics, Inc. (-1.71), greater than Corvus Pharmaceuticals, Inc. (-23.81), less than ALX Oncology Holdings Inc. (-0.45), less than Lyra Therapeutics, Inc. (-0.17), greater than Trevi Therapeutics, Inc. (-7.92), greater than SQZ Biotechnologies Company (-3.78), less than Protara Therapeutics, Inc. (-1.35), less than TRACON Pharmaceuticals, Inc. (0.02), less than Vaccinex, Inc. (-0.33), greater than Monopar Therapeutics Inc. (-8.34), greater than Miromatrix Medical Inc. (-3.41), less than Surrozen, Inc. (-0.70), greater than Monte Rosa Therapeutics, Inc. (-4.83), less than PMV Pharmaceuticals, Inc. (-1.73), greater than Pharvaris N.V. (-10.46), greater than Tyra Biosciences, Inc. (-11.91), greater than Molecular Partners AG (-3.01), greater than Cabaletta Bio, Inc. (-2.20), less than Viracta Therapeutics, Inc. (-0.17), greater than EyePoint Pharmaceuticals, Inc. (-7.17), greater than Biomea Fusion, Inc. (-2.22),

Build a custom stock screener for Rani Therapeutics Holdings, Inc. (RANI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rani Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rani Therapeutics Holdings, Inc. (RANI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rani Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.